These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 17060861)
21. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Kim JH; Kang TH; Noh KH; Bae HC; Kim SH; Yoo YD; Seong SY; Kim TW Immunol Lett; 2009 Jan; 122(1):58-67. PubMed ID: 19135479 [TBL] [Abstract][Full Text] [Related]
22. Splenic dendritic cells pulsed with Ixodes ricinus tick saliva prime naive CD4+T to induce Th2 cell differentiation in vitro and in vivo. Mejri N; Brossard M Int Immunol; 2007 Apr; 19(4):535-43. PubMed ID: 17344202 [TBL] [Abstract][Full Text] [Related]
23. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781 [TBL] [Abstract][Full Text] [Related]
24. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330 [TBL] [Abstract][Full Text] [Related]
26. Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency. Yoshikawa T; Niwa T; Mizuguchi H; Okada N; Nakagawa S Gene Ther; 2008 Oct; 15(19):1321-9. PubMed ID: 18480845 [TBL] [Abstract][Full Text] [Related]
27. Immune synapses formed with measles virus-infected dendritic cells are unstable and fail to sustain T cell activation. Shishkova Y; Harms H; Krohne G; Avota E; Schneider-Schaulies S Cell Microbiol; 2007 Aug; 9(8):1974-86. PubMed ID: 17394561 [TBL] [Abstract][Full Text] [Related]
28. In vitro activation and differentiation of naïve CD4+ and CD8+ T cells into HCV core- and NS3-specific armed effector cells: a new role for CD4+ T cells. Krishnadas DK; Li W; Kumar R; Tyrrell LJ; Agrawal B Cell Immunol; 2009; 259(2):141-9. PubMed ID: 19616202 [TBL] [Abstract][Full Text] [Related]
29. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620 [TBL] [Abstract][Full Text] [Related]
30. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro. Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994 [TBL] [Abstract][Full Text] [Related]
31. Protective immunity elicited by measles vaccine exerts anti-tumor effects on measles virus hemagglutinin gene-modified cancer cells in a mouse model. Qi Y; Xing K; Zhang L; Zhao F; Yao M; Hu A; Wu X J Cancer Res Clin Oncol; 2018 Oct; 144(10):1945-1957. PubMed ID: 30090962 [TBL] [Abstract][Full Text] [Related]
32. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine. Wingard JB; Anderson B; Weissman D Eur J Immunol; 2008 May; 38(5):1310-20. PubMed ID: 18412164 [TBL] [Abstract][Full Text] [Related]
33. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination. Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415 [TBL] [Abstract][Full Text] [Related]
35. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Zhang Y; Ma B; Zhou Y; Zhang M; Qiu X; Sui Y; Zhang X; Ma B; Fan Q Breast Cancer Res Treat; 2007 Nov; 105(3):277-86. PubMed ID: 17187233 [TBL] [Abstract][Full Text] [Related]
36. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency. Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483 [TBL] [Abstract][Full Text] [Related]
37. Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination. Svane IM; Nikolajsen K; Johnsen HE Scand J Immunol; 2007 Oct; 66(4):465-75. PubMed ID: 17850592 [TBL] [Abstract][Full Text] [Related]
38. [The cell-mediated response after measles vaccination]. Pala S; Crimaldi G; Consolini R; Macchia P Pediatr Med Chir; 1998; 20(3):213-6. PubMed ID: 9744016 [TBL] [Abstract][Full Text] [Related]
39. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model. Jack AM; Aydin N; Montenegro G; Alam K; Wallack M J Surg Res; 2007 May; 139(2):164-9. PubMed ID: 17275030 [TBL] [Abstract][Full Text] [Related]
40. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]